|
Sections |
| Title |
|---|
| Executive Summary |
| Scope of the analysis |
| Datamonitor insight into the hormone receptor-negative breast cancer market |
| Contributing experts |
| Related reports |
| Upcoming related reports |
| OVERVIEW |
| Catalyst |
| Summary |
| 1. INTRODUCTION AND SCOPE |
| Coverage of the Stakeholder Insight Survey |
| Epidemiology |
| Treatment options |
| Treatment trends |
| Future treatment |
| 2. EPIDEMIOLOGY |
| Introduction and background |
| Key points |
| Disease definition and diagnosis criteria |
| Global variation and historical trends |
| Incidence rates |
| Prevalence |
| Risk factors |
| Reproductive factors |
| Exogenous hormones |
| Lifestyle factors |
| Socioeconomic factors |
| Genetic predisposition |
| Epidemiologic forecasting of breast cancer |
| Sources of epidemiologic data |
| Categorization and stratification |
| Description of methods |
| Statistical analysis |
| Epidemiologic forecast results |
| Estimated incident cases and future trends of breast cancer |
| Segmentation of incident cases: 2010 |
| Estimated prevalent cases |
| Discussion |
| US |
| Japan |
| Europe |
| Strengths of our epidemiologic projections |
| Conclusions |
| 3. DISEASE OVERVIEW |
| Introduction |
| Breast cancer is the most common tumor type in females |
| Anatomy of the breast |
| Histology of breast cancer |
| Patient segmentation |
| Staging of breast cancer |
| Molecular markers for breast cancer |
| 4. TREATMENT OPTIONS |
| Introduction |
| Overview of breast cancer treatment options |
| Overview of drug therapies approved for hormone receptor-negative breast cancer |
| Treatment options and treatment outcomes in early-stage (Stage I-III) breast cancer |
| Treatment options and treatment outcomes in metastatic (Stage IV) breast cancer |
| 5. TREATMENT TRENDS: STAGE I-III |
| Triple-negative breast cancer |
| Treatment rates |
| Neoadjuvant therapy |
| Adjuvant therapy |
| HER-2-positive breast cancer |
| Treatment rates |
| Neoadjuvant therapy |
| Adjuvant therapy |
| 6. TREATMENT TRENDS: STAGE IV AND RELAPSE |
| Triple-negative breast cancer |
| Stage IV at initial diagnosis |
| Local relapse |
| Distant relapse |
| HER-2-positive breast cancer |
| Stage IV at initial diagnosis |
| Local relapse |
| Distant relapse |
| 7. FUTURE TREATMENT |
| Late-phase pipeline products overview |
| Afatinib (BIBW-2992; Boehringer Ingelheim) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Afinitor (everolimus; Novartis) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Iniparib (BSI-201; BiPar Sciences/Sanofi-Aventis) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Eribulin (E7389; Eisai) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Neratinib (HKI-272; Pfizer) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Pertuzumab (Genentech/Roche/Chugai) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Ramucirumab (IMC-1121B; Eli Lilly) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Trastuzumab-DM1 (ImmunoGen/Genentech/Roche/Chugai) |
| Drug overview |
| Drug profile |
| Key historical events |
| Clinical trial data |
| Clinical and commercial attractiveness |
| Votrient (pazopanib; GlaxoSmithKline) |
| Drug overview |
| Drug profile |
Key historical events
Clinical trial data
Clinical and commercial attractiveness
Future treatment scenarios
Triple-negative breast cancer future treatment scenarios
HER-2-positive breast cancer future treatment scenarios
BIBLIOGRAPHY
Chapter 2. Epidemiology
Journal papers
Chapter 3. Disease Overview
Journal papers
Websites
Chapter 4. Treatment Options
Journal papers
Websites
Chapter 5. Treatment Trends: Stage I-III Breast Cancer
Journal papers
Websites
Datamonitor reports
Other
Chapter 6. Treatment Trends: Stage IV and Relapsed Breast Cancer
Journal papers
Websites
Other
Chapter 7. Future Treatment
Journal papers
Websites
Other
APPENDIX A
Abbreviations
Physician research methodology
Physician sample breakdown
Contributing experts
APPENDIX B
The survey questionnaire
Screener
Introduction
Section 2 - Neoadjuvant and adjuvant chemotherapy for Hormone receptor negative/ HER-2-positive patients
Section 3 - Neoadjuvant and adjuvant chemotherapy for Triple-negative (ER-negative, PR-negative and HER-2-negative) patients
Section 4 - Stage IV disease
Section 5 - Local relapse
Section 6 - Distant relapse
Section 7 - Future scenarios
Datamonitor consulting
Disclaimer |
